Browse drugs

… antibody in calcinosis patients, followed by RNAP3 (16.4%) and Scl-70 (13.7%). Patients with calcinosis were more likely to have RNAP…

…n tests (figure 4).Conclusions Contrary to general assumptions, ACA-positive patients are not uniformly protected from disease progression. …

…onthly CYC pulses (750 mg/m 2) followed by at least one year of mycophenolate mofetil. Criteria for rescue HSCT or DMARD use post-HSCT were predefine…

…presented in table 2. 98% used stimulant drugs, most frequently MDPV (77%). While clients most frequently practiced chemsex weekly (…

…Background Long-acting cabotegravir (CAB-LA) is a key addition to HIV prevention but requires more resource…

…ur hours post-infection, cells were treated with the antibodies plozalizumab (anti-CCR2) or PRO-140 (anti-CCR5). In selected experiments, fr…

…ed PWH (≥18 years, on ART, HIV RNA <50 copies/mL) receiving two HZ/su vaccine doses 2–6 months apart. Peripheral blood samples were c…

…eover, iron chelation prevents or even reverts lung fibrosis in bleomycin models. While the potential pathogenic role of iron in Systemic…

…ce and their littermate controls were treated with subcutaneous bleomycin or PBS injections. To investigate the direct effect of leptin, …

… controls. The eGC reduction was prevented by co-treatment with losartan, confirming that the effect is AT1R-dependent. Despite these me…

…ncrease (38%, p = 0.07).Conclusions In this multicenter cohort, nintedanib was associated with a significant reduction in ILD progression,…

… of corticosteroids (p 0.005), CYC (p 0.034), RTX (p 0.039) and Ninte (p 0.011) was higher in patients with PPF. Similarly, they rece…